NCT02870231 is a Phase 1 clinical trial of NNC9204-0530 in Metabolism and Nutrition Disorder, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT02870231?

NCT02870231 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT02870231?

Interventions in NCT02870231: NNC9204-0530, liraglutide, placebo.

What condition does NCT02870231 study?

NCT02870231 studies Metabolism and Nutrition Disorder, Obesity.

Is NCT02870231 still recruiting?

NCT02870231 is currently completed. Last updated 5 September 2018.

Last reviewed 2018-09-05 · How we verify

NCT02870231

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

Completed Phase 1 Last updated 5 September 2018

What this trial tests

Phase 1 trial testing NNC9204-0530 in Metabolism and Nutrition Disorder in 187 participants. Completed in 3 September 2017.

Timeline

18 August 2016

Primary endpoint
3 September 2017

3 September 2017

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	187
Start date	18 August 2016
Primary completion	3 September 2017
Estimated completion	3 September 2017
Sites	2 locations across United States

Drugs / interventions tested

NNC9204-0530 — full drug profile →
liraglutide (liraglutide) — full drug profile →
placebo

Conditions studied

Metabolism and Nutrition Disorder — all drugs for Metabolism and Nutrition Disorder →
Obesity — all drugs for Obesity →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Adults 18 to 55, any sex, with Metabolism and Nutrition Disorder or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for Multiple Doses of NNC9204-0530 in Combination with Liraglutide in Male and Female Subjects being Overweight or with Obesity

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The incretin/glucagon system as a target for pharmacotherapy of obesity.
Del Prato S, Gallwitz B, Holst JJ, Meier JJ. · · 2022 · cited 53× · PMID 34713962 · DOI 10.1111/obr.13372
Beyond Glucagon-like Peptide-1: Is G-Protein Coupled Receptor Polypharmacology the Path Forward to Treating Metabolic Diseases?
Sloop KW, Briere DA, Emmerson PJ, Willard FS. · · 2018 · cited 30× · PMID 32219200 · DOI 10.1021/acsptsci.8b00009

Verify or expand the search:

Other trials of NNC9204-0530

Trials testing the same drug.

NCT02835235 — A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Bei · Phase 1 · completed
NCT02235961 — Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Lir · Phase 1 · completed

Other recruiting trials for Metabolism and Nutrition Disorder

Currently open trials in the same condition.

NCT05785221 — Energy Metabolism Profiles Over Weight-loss and Eating Responses · NA · active not recruiting
NCT03669809 — The Biological Rhythm of Human Metabolite · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02870231 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 5 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02870231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing